Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DO-IT – The DOAC Intravenous Thrombolysis Trial
2024-515561-34-01Phase 4Authorised
- Sponsor
- Insel Gruppe
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 4, randomised trial in ischemic stroke comparing Tenecteplase arm with Alteplase arm (2 arms). Primary endpoint: modified Rankin Scale (mRS) shift at 90 days. Planned start Aug 2025; status: authorised.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-515561-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515561-34-01.